IRIDEX Corporation (IRIX)vsMerck & Company Inc (MRK)
IRIX
IRIDEX Corporation
$1.03
0.00%
HEALTHCARE · Cap: $18.69M
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 123319% more annual revenue ($65.01B vs $52.67M). MRK leads profitability with a 28.1% profit margin vs -8.4%. IRIX appears more attractively valued with a PEG of 0.94. MRK earns a higher WallStSmart Score of 59/100 (C).
IRIX
Hold38
out of 100
Grade: F
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+82.1%
Fair Value
$8.00
Current Price
$1.03
$6.97 discount
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
16.0% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -126.4% — below average capital efficiency
Currently unprofitable
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : IRIX
The strongest argument for IRIX centers on PEG Ratio, Revenue Growth. Revenue growth of 16.0% demonstrates continued momentum. PEG of 0.94 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : IRIX
The primary concerns for IRIX are EPS Growth, Market Cap, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
IRIX profiles as a growth stock while MRK is a value play — different risk/reward profiles.
IRIX carries more volatility with a beta of 0.76 — expect wider price swings.
IRIX is growing revenue faster at 16.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 38/100), backed by strong 28.1% margins. IRIX offers better value entry with a 82.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IRIDEX Corporation
HEALTHCARE · MEDICAL DEVICES · USA
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?